An advanced practice provider (APP)-led peer review quality assurance (QA) committee was found to be feasible and identified ...
The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback